3 Stocks Near 52-Week Lows Worth Buying

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Just as we examine companies each week that may be rising past their fair value, we can also find companies potentially trading at bargain prices. While many investors would rather have nothing to do with companies tipping the scales at 52-week lows, I think it makes a lot of sense to determine whether the market has overreacted to the downside, just as we often do when the market reacts to the upside.

Here's a look at three fallen angels trading near their 52-week lows that could be worth buying.

Luck of the Irish?
Earlier this month I highlighted Irish women's health pharmaceutical company Warner Chilcott (Nasdaq: WCRX  ) , following a sizable tumble because of a $560 million sale of stock by a consortium of holders in the stock. The move came shortly after the company took itself off the auction block and financed a $1 billion dividend payment by borrowing $600 million from a revolving credit facility. Under normal circumstances, I'd be avoiding moves of this nature like the plague -- seriously, who goes into debt to pay out a dividend?!

However, there are other reasons to be optimistic about Warner Chilcott's future. For one, outside of the one-time dividend payment, the company did declare an annual dividend of $0.50, to be paid semi-annually. At $0.50, Warner Chilcott instantly goes from paying zero in dividends to yielding close to 4%, which places it on par with the yield of many big pharmaceutical companies. Second, although sales of Warner Chilcott's leading drug, Actonel, have been weakening rapidly around the world, I do anticipate that sales weakness here will taper toward the end of the year and that its new product, Atelvia, should cancel out any Actonel weakness by as early as next year. Finally, the valuation just makes sense -- especially with Jazz Pharmaceuticals (Nasdaq: JAZZ  ) selling its women's health business to Meda for $95 million. I know Warner Chilcott is no longer on the auction block, but at just three times cash flow, it's going to draw a lot of attention.

Keep on trucking
If you're curious, yes, I do apparently have a minor fascination with the trucking sector lately. This week I want to take a closer look at Marten Transport (Nasdaq: MRTN  ) , a North American trucker that transports foods and products that are temperature-specific.

As with many logistics companies, slowing global demand, shrinking consumer spending, and rising fuel and labor costs present an immediate threat. Marten has done a very good job of bucking the majority of these trends by focusing on cost controls and improving its efficiency, as well as passing along reasonable price increases. In the second quarter, Marten was able to generate slightly higher revenue from fuel surcharges, but the real gains were derived from an 830-basis-point improvement in regional truck usage aided by a 5.4% improvement in average truckload revenue. Marten's dividend isn't much to look at and is definitely not the reason to buy the stock, but its consistent performance in light of rising fuel prices demonstrates that a strong and fiscally sound management team is leading this company. Now that is a reason to buy Marten Transport!

Jolly green Japanese giant
To round out the week, I want to delve back into a category I haven't touched for months, but is usually a great source of dividend payments: foreign telecoms. Specifically, let's take a closer look at NTT DoCoMo (NYSE: DCM  ) , Japan's largest wireless operator.

You'd think that with half of Japan's market share, NTT DoCoMo would be having its way with competitors in Japan, but that hasn't exactly been the case. NTT's earnings have stagnated in recent years as its privately held peers have created headwinds against the company. But it's entering two new phases in its growth period that should once again swing the tide back to NTT.

To begin with, growth in smartphone sales has been phenomenal and upsells of data packages should give NTT a big margin boost beginning in the next couple of quarters. In its first-quarter report, NTT noted that it nearly doubled its smartphone unit sales to 2.49 million. Second, and most important, NTT is the mobile payment kingpin in Japan. Wireless service providers in the U.S. have struggled with this particular aspect of development and are currently ceding revenue to eBay (Nasdaq: EBAY  ) , whose PayPal service is arguably the best-positioned mobile payment platform in the United States. With mobile payment usage still in its infancy, NTT's growth could actually be on the verge of exploding higher. Let me also not forget to mention that NTT pays a remarkably strong 4% yield and is a relatively nonvolatile investment -- perfect for value and income seekers.

Foolish roundup
No magic voodoo spells this week; just three companies that are doing a good job at controlling costs and are valued at a reasonable price.

I'm so confident that these three names will bounce off their lows that I'm going to make a CAPScall of outperform on each one.

In the meantime, consider adding these potential winners to your free and personalized Watchlist -- and get your own personal copy of our special report "The Motley Fool's Top Stock for 2012" to see which company our chief investment officer has dubbed the "Costco of Latin America." Best of all, this report is completely free, so don't miss out!

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of Costco. Motley Fool newsletter services have recommended buying shares of eBay and Costco. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy that's always on the lookout for a good deal.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2031012, ~/Articles/ArticleHandler.aspx, 10/23/2016 4:12:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:04 PM
DCM $24.10 Down -0.55 -2.23%
NTT DoCoMo CAPS Rating: ***
MRTN $20.10 Up +0.50 +2.55%
Marten Transport CAPS Rating: No stars
WCRX.DL $0.00 Down +0.00 +0.00%
Warner Chilcott CAPS Rating: *****
EBAY $29.06 Up +0.04 +0.14%
eBay CAPS Rating: ****
JAZZ $121.26 Down -0.35 -0.29%
Jazz Pharmaceutica… CAPS Rating: ****